Applied Therapeutics, Inc. (NASDAQ:APLT) Given Consensus Rating of "Moderate Buy" by Brokerages

Applied Therapeutics, Inc. (NASDAQ:APLT - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $6.10.

APLT has been the subject of a number of recent research reports. Royal Bank of Canada restated a "sector perform" rating and set a $1.50 price target on shares of Applied Therapeutics in a research note on Wednesday, May 14th. Wall Street Zen raised shares of Applied Therapeutics to a "sell" rating in a research report on Thursday, May 22nd.

Institutional Investors Weigh In On Applied Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of APLT. CreativeOne Wealth LLC boosted its holdings in Applied Therapeutics by 132.2% during the 1st quarter. CreativeOne Wealth LLC now owns 50,413 shares of the company's stock worth $25,000 after acquiring an additional 28,701 shares during the last quarter. Ground Swell Capital LLC purchased a new position in Applied Therapeutics during the fourth quarter worth about $27,000. Toronto Dominion Bank bought a new stake in Applied Therapeutics in the 4th quarter worth about $27,000. Private Advisor Group LLC purchased a new stake in Applied Therapeutics in the 4th quarter valued at about $35,000. Finally, SG Americas Securities LLC increased its stake in Applied Therapeutics by 169.0% in the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock valued at $35,000 after buying an additional 25,601 shares during the last quarter. 98.31% of the stock is owned by hedge funds and other institutional investors.

Applied Therapeutics Price Performance

Shares of APLT traded down $0.01 during trading hours on Friday, hitting $0.37. The stock had a trading volume of 1,756,455 shares, compared to its average volume of 3,368,871. Applied Therapeutics has a 1-year low of $0.30 and a 1-year high of $10.62. The firm has a market capitalization of $52.81 million, a P/E ratio of -0.23 and a beta of 1.86. The firm has a 50 day simple moving average of $0.39 and a 200-day simple moving average of $0.85.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last released its quarterly earnings data on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). The firm had revenue of $0.00 million during the quarter, compared to analysts' expectations of $0.61 million. Equities analysts predict that Applied Therapeutics will post -0.65 EPS for the current fiscal year.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.